Early clinical experience with imatinib in COVID-19: Searching for a dual effect

Morales‐Ortega, Alejandro; Rivas-Prado, Luis; Frutos‐Pérez, Begoña; Jaenes‐Barrios, Beatriz; Farfán-Sedano, Ana Isabel; García-Parra, Carlos Javier; Hernández-Muniesa, Belén; Duarte‐Millán, Miguel Ángel; Madroñal-Cerezo, Elena; Ontañón‐Nasarre, Ana; Ruiz-Giardín, José Manuel; Bermejo, Fernando; García‐Gil, Mario; Gonzalo-Pascua, Sonia; Martín‐López, Juan Víctor San; Bello, David

doi:10.1016/j.jinf.2021.02.002

Cited by 7 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent in vitro study conducted by Lin et al showed that imatinib can effectively prevent SARS‐CoV‐2 infection with low toxicity. 73 Morales‐Ortega et al 40 in a study monitored the COVID‐19 patients treated with imatinib. Seventeen of 20 patients recovered and three patients died.…”

Section: Discussionmentioning

confidence: 99%

“… 34 , 35 , 36 Imatinib drew attention after the emergence of SARS‐CoV‐2 again and some studies evaluated its potential benefits against COVID‐19 by clinical trials and in vivo/in vitro experiments. 37 , 38 , 39 Although some studies claimed that imatinib may have potential effects against COVID‐19, 40 others cast doubt on its efficacy. 41 , 42 …”

Section: Introductionmentioning

confidence: 99%

“…[34][35][36] Imatinib drew attention after the emergence of SARS-CoV-2 again and some studies evaluated its potential benefits against COVID-19 by clinical trials and in vivo/in vitro experiments. [37][38][39] Although some studies claimed that imatinib may have potential effects against COVID-19, 40 others cast doubt on its efficacy. 41,42 Infliximab is a chimeric monoclonal antibody of human tumor necrosis factor-α (TNF-α) which is used in the treatment of intestinal Behçet's disease (BD), 43,44 Crohn's disease, 45 ulcerative colitis, 46,47 rheumatoid arthritis, 48 ankylosing spondylitis, 49 nail psoriasis, 50 moderate-to-severe plaque psoriasis, 51 resistant psoriatic arthritis, 52 refractory psoriasis including pustular psoriasis, and psoriatic erythroderma.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence

Amani

Zareei

Amani

et al. 2022

Immunity Inflam & Disease

View full text Add to dashboard Cite

Background and Objective Despite the pervasive vaccination program against coronavirus disease 2019 (COVID‐19), people who got fully vaccinated are still contaminated by severe acute respiratory syndrome coronavirus 2, making an effective and safe therapeutic intervention a crucial need for the patients' survival. The purpose of the present study is to seek available evidence for the efficacy and safety of three promising medications artesunate, imatinib, and infliximab against COVID‐19. Methods A literature search was conducted in PubMed, Cochrane Library, medRxive, and Google Scholar, and the relevant articles published up to January 2022 were found. Furthermore, the clinical trial databases were screened for finding more citations. Data analysis was carried out applying The Cochrane Collaboration tool and Newcastle–Ottawa scale to assess the included studies. Meta‐analysis was performed using RevMan 5.4.1. Results Five published studies were identified as eligible. Meta‐analysis showed that there was no significant difference between the infliximab and control groups in terms of mortality rate (risk ratio [RR]: 0.65; confidence interval [CI] 95%: 0.40–1.07; p = .09). However, a significant difference was observed between the two groups for the hospital discharge (RR: 1.37; CI 95%: 1.04–1.80; p = .03). No remarkable clinical benefit was observed for using imatinib in COVID‐19 patients. Artesunate showed significant improvement in patients with COVID‐19. Conclusion In the present, limited evidence exists for the efficacy and safety of artesunate, imatinib, and infliximab in patients with COVID‐19. The findings of WHO's Solidarity international trial will provide further information regarding these therapeutic interventions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence

Amani

Zareei

Amani

et al. 2022

Immunity Inflam & Disease

View full text Add to dashboard Cite

show abstract

“…This is the case of imatinib, the principal BCR-Abl inhibitor for the treatment of chronic myeloid leukaemia (CML), which has been proposed as a potential treatment for SARS-CoV-2 infection, as it may exhibit both antiviral and immunomodulatory properties. 2 Indeed, a recent randomised controlled trial on the use of imatinib in severe COVID-19 has yielded encouraging results. 3 However, concerns have been raised regarding possible interferences of this kind of tyrosine kinase inhibitors (TKI) with B-cell response.…”

mentioning

confidence: 99%

Antibody formation against SARS-CoV-2 in imatinib-treated COVID-19 patients

Morales‐Ortega

Farfán-Sedano

Izquierdo-Martínez

et al. 2022

Journal of Infection

Self Cite

View full text Add to dashboard Cite

“…Imatinib mesilate, the main BCR–ABL tyrosine-kinase inhibitor, might fulfil these criteria. Although the potential of imatinib has scarcely been explored in COVID-19, 1 this drug has been widely used as first-line therapy in chronic myeloid leukaemia and is also indicated for other conditions (eg, gastrointestinal stromal tumours), showing a safety profile that could be considered optimal since its first approval 20 years ago. During this time, other potential effects of imatinib have been identified, such as antiviral properties against other β-coronaviruses in vitro by hindering the early stages of the virus lifecycle.…”

mentioning

confidence: 99%